Credit Suisse’s Serina Therapeutics SER Stock Holding History

Credit Suisse’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-781	Closed	-$26K	–	4154
2020 Q2	$26K	Buy	+781	New	+$23K	﹤0.01%	3907

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

SWIG

Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Credit Suisse's SER Position: Q3 2020 in Review

Credit Suisse sold out of Serina Therapeutics (SER) in Q3 2020, closing a stake of 781 shares — an estimated $26K sold.

Credit Suisse first reported a position in SER in Q2 2020 and held it in 1 quarter. The position peaked at $26K in Q2 2020. 36 funds tracked by Wall St. Rank hold SER as of Q3 2020.

Credit Suisse reported no remaining Serina Therapeutics position as of Q3 2020 after selling out during the quarter.
Credit Suisse sold 781 Serina Therapeutics shares in Q3 2020, an estimated $26K.
Credit Suisse first reported a position in Serina Therapeutics in Q2 2020 and held it in 1 quarter.
Credit Suisse's Serina Therapeutics position peaked at $26K in Q2 2020.
36 funds tracked by Wall St. Rank held Serina Therapeutics as of Q3 2020.

Based on Credit Suisse's 13F filing for Q3 2020, filed 13 Nov 2020.